Abstract:PurposeCalcineurin inhibitors are considered the backbone of lung transplant immunosuppression regimens. When used de novo, tacrolimus has been shown to be associated with fewer acute rejection episodes compared to cyclosporine. However, conflicting evidence exists regarding the superiority of tacrolimus or cyclosporine in preventing bronchiolitis obliterans syndrome (BOS). Furthermore, the effect of these drugs on fibroproliferation ultimately leading to BOS remains to be investigated.MethodsThe effect of tacrolimus and cyclosporine on collagen synthetic function of mesenchymal cells isolated from patients with BOS was investigated by western blot analysis. Furthermore, we investigate if conversion to cyclosporine at later time point post-lung transplantation can effect development of BOS. Patients transplanted between 2005-2012 at our institution were reviewed. Patients who were converted to cyclosporine greater 180 days post-transplant and had no evidence of BOS were compared to patients who continued on tacrolimus therapy. All patients received an antiproliferative agent and prednisone. Time to BOS was analyzed by Kaplan Meier.ResultsBOS mesenchymal cells treated with cyclosporine (5Âµm) demonstrated 76% decrease in baseline collagen protein expression (n=8, p = 0.0017). In comparison, BOS mesenchymal cells treated with tacrolimus (5ÂµM) demonstrated no significant decline in collagen (n=6, p = 0.48). 17 of 200 (8.5%) patients transplanted between 2005-2012 were switched to cyclosporine post-transplant for a variety of reasons. Median time to conversion was 377 days (159-1968 days). Cyclosporine group was compared to 124 tacrolimus patients. Cyclosporine patients had a trend towards increased BOS free survival as compared to tacrolimus group (p value= 0.07 log rank test).ConclusionCyclosporine has a superior anti-fibrotic action on mesenchymal cells, and patients who were converted to it later than 180 days post-transplant have a lower rate of BOS. These findings bring forward the need to design future clinical studies investigating the utility and optimal timing of conversion to cyclosporine offsetting the risk of acute rejection. PurposeCalcineurin inhibitors are considered the backbone of lung transplant immunosuppression regimens. When used de novo, tacrolimus has been shown to be associated with fewer acute rejection episodes compared to cyclosporine. However, conflicting evidence exists regarding the superiority of tacrolimus or cyclosporine in preventing bronchiolitis obliterans syndrome (BOS). Furthermore, the effect of these drugs on fibroproliferation ultimately leading to BOS remains to be investigated. Calcineurin inhibitors are considered the backbone of lung transplant immunosuppression regimens. When used de novo, tacrolimus has been shown to be associated with fewer acute rejection episodes compared to cyclosporine. However, conflicting evidence exists regarding the superiority of tacrolimus or cyclosporine in preventing bronchiolitis obliterans syndrome (BOS). Furthermore, the effect of these drugs on fibroproliferation ultimately leading to BOS remains to be investigated. MethodsThe effect of tacrolimus and cyclosporine on collagen synthetic function of mesenchymal cells isolated from patients with BOS was investigated by western blot analysis. Furthermore, we investigate if conversion to cyclosporine at later time point post-lung transplantation can effect development of BOS. Patients transplanted between 2005-2012 at our institution were reviewed. Patients who were converted to cyclosporine greater 180 days post-transplant and had no evidence of BOS were compared to patients who continued on tacrolimus therapy. All patients received an antiproliferative agent and prednisone. Time to BOS was analyzed by Kaplan Meier. The effect of tacrolimus and cyclosporine on collagen synthetic function of mesenchymal cells isolated from patients with BOS was investigated by western blot analysis. Furthermore, we investigate if conversion to cyclosporine at later time point post-lung transplantation can effect development of BOS. Patients transplanted between 2005-2012 at our institution were reviewed. Patients who were converted to cyclosporine greater 180 days post-transplant and had no evidence of BOS were compared to patients who continued on tacrolimus therapy. All patients received an antiproliferative agent and prednisone. Time to BOS was analyzed by Kaplan Meier. ResultsBOS mesenchymal cells treated with cyclosporine (5Âµm) demonstrated 76% decrease in baseline collagen protein expression (n=8, p = 0.0017). In comparison, BOS mesenchymal cells treated with tacrolimus (5ÂµM) demonstrated no significant decline in collagen (n=6, p = 0.48). 17 of 200 (8.5%) patients transplanted between 2005-2012 were switched to cyclosporine post-transplant for a variety of reasons. Median time to conversion was 377 days (159-1968 days). Cyclosporine group was compared to 124 tacrolimus patients. Cyclosporine patients had a trend towards increased BOS free survival as compared to tacrolimus group (p value= 0.07 log rank test). BOS mesenchymal cells treated with cyclosporine (5Âµm) demonstrated 76% decrease in baseline collagen protein expression (n=8, p = 0.0017). In comparison, BOS mesenchymal cells treated with tacrolimus (5ÂµM) demonstrated no significant decline in collagen (n=6, p = 0.48). 17 of 200 (8.5%) patients transplanted between 2005-2012 were switched to cyclosporine post-transplant for a variety of reasons. Median time to conversion was 377 days (159-1968 days). Cyclosporine group was compared to 124 tacrolimus patients. Cyclosporine patients had a trend towards increased BOS free survival as compared to tacrolimus group (p value= 0.07 log rank test). ConclusionCyclosporine has a superior anti-fibrotic action on mesenchymal cells, and patients who were converted to it later than 180 days post-transplant have a lower rate of BOS. These findings bring forward the need to design future clinical studies investigating the utility and optimal timing of conversion to cyclosporine offsetting the risk of acute rejection. Cyclosporine has a superior anti-fibrotic action on mesenchymal cells, and patients who were converted to it later than 180 days post-transplant have a lower rate of BOS. These findings bring forward the need to design future clinical studies investigating the utility and optimal timing of conversion to cyclosporine offsetting the risk of acute rejection.

Halting BOS in Lung Transplant: is Cyclosporine Conversion the Answer?

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Tacrolimus As a Steroid-Sparing Agent for Adults with Steroid-Dependent Minimal Change Nephrotic Syndrome

Efficacy of tacrolimus versus cyclosporine after lung transplantation: an updated systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Conversion from Cyclosporine to Tacrolimus in Patients with Chronic Allograft Nephropathy

Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy

Systematic review and meta-analysis of calcineurin inhibitors on long-term prognosis of renal transplant patients

Long-term beneficial effect of tacrolimus conversion on renal transplant recipients

Early Initiation of Tacrolimus or Cyclophosphamide Therapy for Idiopathic Membranous Nephropathy with Severe Proteinuria.

Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome.

Comparison of cyclosporine and tacrolimus after liver transplantation for primary biliary cholangitis: A propensity score-matched intention-to-treat registry study

Conversion from Cyclosporine to Tacrolimus in Renal Allograft Recipients with Chronic Allograft Nephropathy: A Prospective Single Center Study

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis

Cyclosporine Sparing with the Use of Myco- Phenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients

Role of Steroid Minimization in the Tacrolimus-Based Immunosuppressive Regimen for Liver Transplant Recipients: a Systematic Review and Meta-Analysis of Prospective Randomized Controlled Trials.

Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation

Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.